Actinium Pharmaceuticals, Inc.ATNMEarnings & Financial Report
NYSE
NextMar 31, 2026
ATNM Q3 2025 Key Financial Metrics
Revenue
$90.0K
Gross Profit
N/A
Operating Profit
$-5.7M
Net Profit
$-5.1M
Gross Margin
N/A
Operating Margin
-6324.4%
Net Margin
-5701.1%
YoY Growth
N/A
EPS
$-0.16
Financial Flow
Actinium Pharmaceuticals, Inc. Q3 2025 Financial Summary
Actinium Pharmaceuticals, Inc. reported revenue of $90.0K for Q3 2025, with a net profit of $-5.1M (-5701.1% margin). Cost of goods sold was N/A, operating expenses totaled N/A.
Key Financial Metrics
| Total Revenue | $90.0K |
|---|---|
| Net Profit | $-5.1M |
| Gross Margin | N/A |
| Operating Margin | -6324.4% |
| Report Period | Q3 2025 |
Actinium Pharmaceuticals, Inc. Annual Revenue by Year
Actinium Pharmaceuticals, Inc. annual revenue history includes year-by-year totals (for example, 2023 revenue was $3.1M).
| Year | Annual Revenue |
|---|---|
| 2023 | $3.1M |
| 2022 | $1.0M |
Income Statement
| Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $45000 | $0 | $547000 | $461000 | $1.1M | $1.0M | $927000 | $90000 |
| YoY Growth | -80.7% | N/A | -41.8% | 924.4% | 2288.9% | N/A | 69.5% | N/A |
Balance Sheet
| Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $116.8M | $114.2M | $102.0M | $99.1M | $88.9M | $81.4M | $88.4M | $56.2M |
| Liabilities | $45.6M | $47.7M | $44.8M | $46.0M | $45.4M | $45.1M | $44.5M | $42.4M |
| Equity | $71.3M | $66.5M | $57.2M | $53.1M | $43.6M | $36.4M | $43.9M | $13.8M |
Cash Flow
| Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-5.7M | $-7.8M | $-15.1M | $-13.6M | $-11.1M | $-7.5M | $-7.4M | $-6.3M |